Advertisement


Harry Klein, PhD, on MatchMiner: An Open-Source AI Precision Medicine Trial Matching Platform

AACR Annual Meeting 2023

Advertisement

Harry Klein, PhD, of Dana-Farber Cancer Institute, discusses MatchMiner, a software platform launched in 2017, that matches patients with appropriate clinical trials of targeted therapies. The platform uses data on the genetic features of a patient’s cancer, as well as clinical data, to identify trials at Dana-Farber for which the patient might be eligible. MatchMiner can also help recruit patients who meet the trial’s eligibility requirements. (Abstract 1067)



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
MatchMiner is an open-source precision medicine trial matching platform developed at Dana-Farber. In 2017, we set out with two main goals. The first is to accelerate enrollment onto precision medicine trials, and the second is to provide more trial options for patients. Here at AACR 2023, we presented on some additional data that's following up our publication in npj Precision Oncology, where we report a clinical impact for MatchMiner. MatchMiner is able to get patients onto trials about 55 days faster compared to other methods that we found, and this is a great benefit for precision medicine trials. We also report on some of the characteristics of our MatchMiner consents. We find a vast array of different genes and cancer types in patients that enroll onto our precision medicine trials. This shows that MatchMiner can help a vast array of different patients across departments at any institution. We are now moving forward with a new study for MatchMiner that uses AI and natural language processing to sort patients after they've matched to trials. The MatchMiner algorithm matches all live patients to all open trials at any given point in time, but most patients are not ready to enroll onto a trial. Therefore, we partnered with Dr. Kenneth Kehl at Dana-Farber to develop a natural language processing model that essentially takes radiology scan text and makes a likelihood prediction if a patient is ready to enroll onto a trial or not. If that patient is ready to enroll into a trial, then we send an email to the oncologist to the patient saying, "Here are all the trial options that are currently available." And this is a study that is ongoing this year and will have results early next year. We currently have two institutions using MatchMiner, Memorial Sloan Kettering and Princess Margaret Cancer Center. For more information on MatchMiner, you can visit our website at matchminer.org and find information about the MatchMiner software on our GitHub links on the website.

Related Videos

Skin Cancer

Jeffrey S. Weber, MD, PhD, on Melanoma: New Data on a Cancer Vaccine Combined With Pembrolizumab

Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center at New York University Langone, discusses efficacy and safety results from the phase II KEYNOTE-942 trial, which showed that a personalized mRNA-based cancer vaccine, combined with the immune checkpoint inhibitor pembrolizumab, improved recurrence-free survival compared with pembrolizumab alone in patients with high-risk melanoma. The clinical benefit was observed regardless of the tumor mutational burden status. (Abstract CT001)

Hepatobiliary Cancer

Pierce K.H. Chow, PhD, MBBS, on Hepatocellular Carcinoma: New Data From the IMbrave050 Trial of Atezolizumab, Bevacizumab, and Active Surveillance

Pierce K.H. Chow, PhD, MBBS, of the National Cancer Centre, Singapore and Duke-NUS Medical School, discusses phase III findings showing that, for patients with hepatocellular carcinoma at high risk of disease recurrence, adjuvant therapy with atezolizumab plus bevacizumab after resection or thermal ablation was more effective than active surveillance. According to Dr. Chow, these results could lead to reassessment of surgical resection in this disease. (Abstract CT003)

Supportive Care
Symptom Management
Breast Cancer
Colorectal Cancer

Lindsay L. Peterson, MD, on Exercise and Cancer Outcomes

Lindsay L. Peterson, MD, of the Washington University, St. Louis, discusses the value of physical activity in improving cancer prognosis, especially for patients with breast or colon cancer. Aerobic exercises and resistance training are recommended during and after treatment. Exercise may help inhibit tumor growth, improve quality of life by decreasing fatigue and anxiety, build muscle mass, increase physical function, and reduce surgical complications and treatment delays.

Issues in Oncology

Karriem S. Watson, DHSc, on Early Engagement in Clinical Trials for Underrepresented Communities

Karriem S. Watson, DHSc, MPH, of the National Institutes of Health All of Us Research Program, discusses the importance of engaging in clinical trials for those who are underrepresented in biomedical research. Community engagement is a proven and effective tool, Dr. Watson says, to enhance participation in research by increasing access to and awareness of medical studies and has already been shown to expand the reach of therapies, improving cancer outcomes. (Abstract PL03-05)

Solid Tumors

Timothy A. Yap, MD, PhD, on New Findings on Treating Solid Tumors With PARP and ATR Inhibitors

Timothy A. Yap, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses safety and efficacy data on three different PARP inhibitors combined with the ATR inhibitor camonsertib in patients with solid tumors harboring DNA damage response alterations. The findings showed that low-dose intermittent regimens of camonsertib and different PARP inhibitor combinations were safe. In addition, anticancer activity was observed in patients with platinum- and PARP inhibitor–resistant tumors. Patients with late-line ovarian cancer derived the most benefit from therapy. (Abstract CT018)

Advertisement

Advertisement




Advertisement